Featuring an interview with Dr Raajit K Rampal, including the following topics:
- Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00)
- Novel research strategies involving CDK4/6 inhibitors for MF (8:03)
- Implications of the JUMP study for clinical practice (10:00)
- Therapeutic switching strategies with JAK inhibitors for MF (12:17)
- Clinical rationale for the use of luspatercept and elritercept for MF (15:35)
- Emerging clinical data involving BET inhibitors for MF (16:57)
- Tolerability concerns with selinexor in patients with MF (20:01)
- Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32)
- Additional novel strategies under clinical investigation for MF (25:52)
- Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40)
- Management of polycythemia vera and essential thrombocythemia (34:27)
- General management principles for myeloproliferative neoplasms (37:53)
CME information and select publications
Research To Practice | Oncology Videos